BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $211,712 | -12.9% | 4,154 | -7.9% | 0.04% | -19.6% |
| Q3 2022 | $243,000 | -9.0% | 4,510 | +8.6% | 0.05% | -6.1% |
| Q2 2022 | $267,000 | -17.1% | 4,152 | 0.0% | 0.05% | -2.0% |
| Q1 2022 | $322,000 | -16.8% | 4,152 | -7.8% | 0.05% | -12.3% |
| Q4 2021 | $387,000 | +6.9% | 4,504 | +0.0% | 0.06% | -3.4% |
| Q3 2021 | $362,000 | 0.0% | 4,502 | +0.0% | 0.06% | 0.0% |
| Q2 2021 | $362,000 | -4.5% | 4,501 | +0.0% | 0.06% | -13.2% |
| Q1 2021 | $379,000 | +5.0% | 4,499 | +0.0% | 0.07% | -1.4% |
| Q4 2020 | $361,000 | -0.3% | 4,498 | +0.0% | 0.07% | -13.8% |
| Q3 2020 | $362,000 | -3.2% | 4,496 | +3.5% | 0.08% | -14.0% |
| Q2 2020 | $374,000 | +5.9% | 4,345 | 0.0% | 0.09% | -14.7% |
| Q1 2020 | $353,000 | -14.5% | 4,345 | -12.1% | 0.11% | +6.9% |
| Q4 2019 | $413,000 | +19.7% | 4,944 | +25.4% | 0.10% | +6.2% |
| Q3 2019 | $345,000 | +6.8% | 3,943 | +0.0% | 0.10% | +3.2% |
| Q2 2019 | $323,000 | -1.8% | 3,942 | -2.4% | 0.09% | -11.4% |
| Q1 2019 | $329,000 | +23.7% | 4,041 | +0.0% | 0.10% | +20.7% |
| Q4 2018 | $266,000 | -31.4% | 4,040 | -19.8% | 0.09% | -17.1% |
| Q3 2018 | $388,000 | +4.3% | 5,039 | +0.0% | 0.10% | 0.0% |
| Q2 2018 | $372,000 | +50.0% | 5,038 | +32.1% | 0.10% | +38.2% |
| Q1 2018 | $248,000 | -20.3% | 3,815 | -20.8% | 0.08% | -20.0% |
| Q4 2017 | $311,000 | +3.0% | 4,815 | +0.0% | 0.10% | -5.0% |
| Q3 2017 | $302,000 | +3.8% | 4,814 | +0.0% | 0.10% | +1.0% |
| Q2 2017 | $291,000 | +16.4% | 4,813 | +0.0% | 0.10% | +13.8% |
| Q1 2017 | $250,000 | +17.4% | 4,812 | +0.0% | 0.09% | +10.1% |
| Q4 2016 | $213,000 | -7.0% | 4,811 | +0.0% | 0.08% | -12.2% |
| Q3 2016 | $229,000 | +2.2% | 4,810 | -3.0% | 0.09% | -5.3% |
| Q2 2016 | $224,000 | +9.8% | 4,959 | +0.0% | 0.10% | +6.7% |
| Q1 2016 | $204,000 | -46.7% | 4,958 | -9.4% | 0.09% | -50.8% |
| Q2 2015 | $383,000 | +0.3% | 5,475 | -1.7% | 0.18% | -1.6% |
| Q1 2015 | $382,000 | -3.8% | 5,570 | +2.9% | 0.18% | -10.7% |
| Q4 2014 | $397,000 | +8.8% | 5,414 | +6.3% | 0.21% | -5.9% |
| Q3 2014 | $365,000 | +3.1% | 5,091 | +0.2% | 0.22% | -4.4% |
| Q4 2013 | $354,000 | +6.0% | 5,083 | +0.1% | 0.23% | -5.8% |
| Q3 2013 | $334,000 | -5.1% | 5,080 | +0.1% | 0.24% | -2.0% |
| Q2 2013 | $352,000 | – | 5,077 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |